The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Major Changes to the 2017 Revision of the World Health Organization Classification of Myeloproliferative Neoplasms

골수증식 종양의 2017년 WHO 진단기준 주요 변경 사항의 이해

  • Jang, Mi-Ae (Department of Laboratory Medicine and Genetics, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine)
  • 장미애 (순천향대학교 의과대학 부천병원 진단검사의학과)
  • Published : 2018.08.01
⟨ Previous Next ⟩

Abstract

The World Health Organization (WHO) Classification of Tumors of Haematopoietic and Lymphoid Tissues was recently published in a revised fourth edition. The categories of myeloproliferative neoplasms (MPNs) have not significantly changed since the 2008 fourth edition of the classification; however, newly discovered mutations including CALR and CSF3R and improved characterizations and standardizations of morphological features of some entities, particularly BCR-ABL1-negative MPNs, have impacted the diagnostic criteria of disease entities, increasing the reliability and reproducibility of diagnoses. The 2017 revised edition attempts to incorporate new clinical, prognostic, morphologic, and genetic data that have emerged since the last edition. This article reviews the major changes in the classification and their rationale for MPN classification within the revised 2017 WHO system.

Keywords

References

  1. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: IARC Press, 2017.
  2. Tefferi A, Guglielmelli P, Larson DR, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood 2014;124:2507-2513. https://doi.org/10.1182/blood-2014-05-579136
  3. Tefferi A, Thiele J, Vannucchi AM, Barbui T. An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms. Leukemia 2014;28:1407-1413. https://doi.org/10.1038/leu.2014.35
  4. Barbui T, Thiele J, Vannucchi AM, Tefferi A. Myeloproliferative neoplasms: morphology and clinical practice. Am J Hematol 2016;91:430-433. https://doi.org/10.1002/ajh.24288
  5. Gianelli U, Bossi A, Cortinovis I, et al. Reproducibility of the WHO histological criteria for the diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms. Mod Pathol 2014;27:814-822. https://doi.org/10.1038/modpathol.2013.196
  6. Gisslinger H, Gotic M, Holowiecki J, et al. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET study, a randomized controlled trial. Blood 2013;121:1720-1728. https://doi.org/10.1182/blood-2012-07-443770
  7. Madelung AB, Bondo H, Stamp I, et al. World Health Organization-defined classification of myeloproliferative neoplasms: morphological reproducibility and clinical correlations--the Danish experience. Am J Hematol 2013;88:1012-1016. https://doi.org/10.1002/ajh.23554
  8. Thiele J, Kvasnicka HM, Mullauer L, Buxhofer-Ausch V, Gisslinger B, Gisslinger H. Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification. Blood 2011;117:5710-5718. https://doi.org/10.1182/blood-2010-07-293761
  9. Barbui T, Thiele J, Gisslinger H, et al. Masked polycythemia vera (mPV): results of an international study. Am J Hematol 2014;89:52-54. https://doi.org/10.1002/ajh.23585
  10. Barosi G, Rosti V, Bonetti E, et al. Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis. PLoS One 2012;7:e35631. https://doi.org/10.1371/journal.pone.0035631
  11. Gianelli U, Iurlo A, Cattaneo D, Lambertenghi-Deliliers G. Cooperation between pathologists and clinicians allows a better diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms. Expert Rev Hematol 2014;7:255-264. https://doi.org/10.1586/17474086.2014.876898
  12. Gisslinger H, Jeryczynski G, Gisslinger B, et al. Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria. Leukemia 2016;30:1126-1132. https://doi.org/10.1038/leu.2015.360
  13. Byun JM, Kim YJ, Youk T, Yang JJ, Yoo J, Park TS. Real world epidemiology of myeloproliferative neoplasms: a population based study in Korea 2004-2013. Ann Hematol 2017;96:373-381. https://doi.org/10.1007/s00277-016-2902-9
  14. Choi CW, Bang SM, Jang S, et al. Guidelines for the management of myeloproliferative neoplasms. Korean J Intern Med 2015;30:771-788. https://doi.org/10.3904/kjim.2015.30.6.771
  15. Hanfstein B, Muller MC, Hochhaus A. Response-related predictors of survival in CML. Ann Hematol 2015;94 Suppl 2:S227-S239. https://doi.org/10.1007/s00277-015-2327-x
  16. Rea D, Etienne G, Nicolini F, et al. First-line imatinib mesylate in patients with newly diagnosed accelerated phase-chronic myeloid leukemia. Leukemia 2012;26:2254-2259. https://doi.org/10.1038/leu.2012.92
  17. Fabarius A, Leitner A, Hochhaus A, et al. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood 2011;118:6760-6768. https://doi.org/10.1182/blood-2011-08-373902
  18. Maxson JE, Gotlib J, Pollyea DA, et al. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med 2013;368:1781-1790. https://doi.org/10.1056/NEJMoa1214514
  19. Pardanani A, Lasho TL, Laborde RR, et al. CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia. Leukemia 2013;27:1870-1873. https://doi.org/10.1038/leu.2013.122
  20. Dong F, Qiu Y, Yi T, Touw IP, Larner AC. The carboxyl terminus of the granulocyte colony-stimulating factor receptor, truncated in patients with severe congenital neutropenia/acute myeloid leukemia, is required for SH2-containing phosphatase-1 suppression of Stat activation. J Immunol 2001;167:6447-6452. https://doi.org/10.4049/jimmunol.167.11.6447
  21. Cui Y, Li B, Gale RP, et al. CSF3R, SETBP1 and CALR mutations in chronic neutrophilic leukemia. J Hematol Oncol 2014;7:77. https://doi.org/10.1186/s13045-014-0077-1
  22. Elliott MA, Tefferi A. Chronic neutrophilic leukemia 2016: update on diagnosis, molecular genetics, prognosis, and management. Am J Hematol 2016;91:341-349. https://doi.org/10.1002/ajh.24284
  23. Lasho TL, Mims A, Elliott MA, Finke C, Pardanani A, Tefferi A. Chronic neutrophilic leukemia with concurrent CSF3R and SETBP1 mutations: single colony clonality studies, in vitro sensitivity to JAK inhibitors and lack of treatment response to ruxolitinib. Leukemia 2014;28:1363-1365. https://doi.org/10.1038/leu.2014.39
  24. Elliott MA, Pardanani A, Hanson CA, et al. ASXL1 mutations are frequent and prognostically detrimental in CSF3R-mutated chronic neutrophilic leukemia. Am J Hematol 2015;90:653-656. https://doi.org/10.1002/ajh.24031
  25. Alvarez-Larran A, Angona A, Ancochea A, et al. Masked polycythaemia vera: presenting features, response to treatment and clinical outcomes. Eur J Haematol 2016;96:83-89. https://doi.org/10.1111/ejh.12552
  26. Barbui T, Thiele J, Carobbio A, et al. Masked polycythemia vera diagnosed according to WHO and BCSH classification. Am J Hematol 2014;89:199-202. https://doi.org/10.1002/ajh.23617
  27. Barbui T, Thiele J, Carobbio A, et al. Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients. Am J Hematol 2014;89:588-590. https://doi.org/10.1002/ajh.23694
  28. Barbui T, Thiele J, Kvasnicka HM, Carobbio A, Vannucchi AM, Tefferi A. Essential thrombocythemia with high hemoglobin levels according to the revised WHO classification. Leukemia 2014;28:2092-2094. https://doi.org/10.1038/leu.2014.175
  29. Thiele J, Kvasnicka HM. The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Curr Hematol Malig Rep 2009;4:33-40. https://doi.org/10.1007/s11899-009-0005-6
  30. Thiele J, Kvasnicka HM, Diehl V. Standardization of bone marrow features--does it work in hematopathology for histological discrimination of different disease patterns? Histol Histopathol 2005;20:633-644.
  31. Thiele J, Kvasnicka HM. Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients. Ann Hematol 2003;82:148-152.
  32. Kvasnicka HM, Thiele J. The impact of clinicopathological studies on staging and survival in essential thrombocythemia, chronic idiopathic myelofibrosis, and polycythemia rubra vera. Semin Thromb Hemost 2006;32(4 Pt 2):362-371. https://doi.org/10.1055/s-2006-942757
  33. Thiele J, Kvasnicka HM. Clinicopathological criteria for differential diagnosis of thrombocythemias in various myeloproliferative disorders. Semin Thromb Hemost 2006;32:219-230. https://doi.org/10.1055/s-2006-939433
  34. Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol 2011;29:573-582.
  35. Tefferi A, Lasho TL, Finke CM, et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia 2014;28:1472-1477. https://doi.org/10.1038/leu.2014.3
  36. Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 2005;90:1128-1132.

Cited by

  1. Recent insights regarding the molecular basis of myeloproliferative neoplasms vol.35, pp.1, 2018, https://doi.org/10.3904/kjim.2019.317
  2. 침치료로 임상증상이 호전된 진성적혈구증가증 환자 치험 1례 vol.42, pp.5, 2021, https://doi.org/10.22246/jikm.2021.42.5.976